What is Joinn Laboratories (China) Co Pre-Tax Income?
Pretax income is the income that a company earns before paying income taxes. Joinn Laboratories (China) Co's pretax income for the
three
months ended in Sep. 2024 was HK$118 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was HK$50 Mil.
Joinn Laboratories (China) Co's pretax margin was 22.12%.
During the past 12 years, Joinn Laboratories (China) Co's highest Pretax Margin was 54.67%. The lowest was 2.12%. And the median was 32.40%.
Joinn Laboratories (China) Co Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Joinn Laboratories (China) Co Pre-Tax Income Chart
Competitive Comparison of Joinn Laboratories (China) Co's Pre-Tax Income
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co's Pre-Tax Income Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's Pre-Tax Income falls into.
Joinn Laboratories (China) Co Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co (HKSE:06127) Pre-Tax Income Explanation
Joinn Laboratories (China) Co's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
During the past 12 years, Joinn Laboratories (China) Co's highest Pretax Margin was 54.67%. The lowest was 2.12%. And the median was 32.40%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Joinn Laboratories (China) Co Business Description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06127 has been successfully added to your 